(Q38091335)

28 August 2017

title

A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer (English)

1 reference

28 August 2017

1 reference

1 reference

Iben Kümler

1 reference

28 August 2017

Nils Brünner

1 reference

28 August 2017

Jan Stenvang

1 reference

28 August 2017

Eva Balslev

1 reference

28 August 2017

Dorte L Nielsen

1 reference

28 August 2017

language of work or name

English

0 references

publication date

20 March 2013

1 reference

Breast Cancer Research and Treatment

28 August 2017

published in

1 reference

28 August 2017

volume

138

1 reference

28 August 2017

1 reference

28 August 2017

page(s)

347-358

1 reference

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Treatment of metastatic breast cancer: second line and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Other Options in the Treatment of Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Topoisomerase 1 inhibitors and cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Clinical development of new formulations of cytotoxics in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

A multicenter, phase I, dose-escalation study to assess the safety, tolerability, and pharmacokinetics of etirinotecan pegol in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Cellular roles of dna topoisomerases: a molecular perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Clinical Pharmacokinetics of Irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Oxaliplatin: a review of approved uses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Irinotecan and bevacizumab in recurrent glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Management strategies for recurrent platinum-resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Review role of topotecan in gynaecological cancers: current indications and perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Single-agent topotecan as first-line chemotherapy in women with metastatic breast cancer: final results of eastern cooperative oncology group trial E8193.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Phase II study of irinotecan plus capecitabine in anthracycline- and taxane- pretreated patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Topotecan chemotherapy in patients with breast cancer and brain metastases: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

1st International consensus guidelines for advanced breast cancer (ABC 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Elevations of DNA topoisomerase I in invasive carcinoma of the breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2476-3

10.1007/S10549-013-2476-3

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1015446780

0 references

1 reference